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CDC PUBLIC HEALTH GRAND ROUNDS  
June 17, 2014 
The 25th Anniversary of the  
Discovery of the Hepatitis C Virus  
Looking Back to Look Forward 
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The Epidemiology of Hepatitis C 
How Did We Get Here?  
John W. Ward, MD 
Director, Division of Viral Hepatitis 
National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
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Key Contributors to the Discovery of HCV 
Harvey Alter Daniel Bradley 
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Discovery of Hepatitis C Virus (HCV) 
 Discovered in 1989, RNA virus, family Flaviviridae 
 9,600 nucleotide genome-single polyprotein  
 Structural proteins  
 Non-structural proteins - viral replication and targets of therapy 
 High genetic diversity leads to intra-host variants “quasispecies” 
 7 major genotypes that predict treatment response  
 Genotype 1 accounts for ~ 70% of infections in US 
 No vaccine candidates for licensure   
 
 
Lindenbach BD, Fields Virology 2001.  Simmonds P, Hepatology 1995.  Irshad M, Hepatogastroenterology 2010.   
Manos MM, J Med Virol 2012.  
Serine protease 
RNA helicase  
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Global Burden of HCV Infection, 2005  
HCV: Hepatitis C virus.   
 
Estimated from: Hanafiah K, Hepatology  2012.  Lozano R, Lancet  2012. 
135 million persons living with HCV   
500,000 deaths per year  
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Prevalence of Current HCV Infection Among 
Persons in the United States   
  
NHANES: National Health and Nutrition Examination Survey. 
 
Denniston M, Ann Int Med 2014.  Chak E, Liver Int 2011.   
 Prevalence in United States ~3 million  
 
 NHANES prevalence estimate 
 2.7 million individuals (2.2-3.2 million) 
 1.0% (0.8%-1.2%)  
 Civilian, non-institutionalized populations 
 
 Non-NHANES prevalence estimate 
 360,000-840,000 
 22%-52% of those incarcerated 
 Homeless or incarcerated persons 
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Impact of Prevention Measures  
on HCV in United States 
Jagger J, J Infect Dis Pub Health 2008.  Ward JW. Clin Liver Dis, 2013. CDC.gov/hepatitis 
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Recent Increases in HCV Infection 
PWID: Persons who inject drugs. 
 
CDC unpublished data. 
 
 
 Between 2007 and 2012 
 50% increase in case reporting 
 200% increase in 17 states 
 
 Risk factors  
 ~ 70% persons who inject drugs 
 Previous oral prescription 
narcotic use   
 Equally male to female  
 Young, ages 18 to 29 years 
 Rural and suburban 
 White  
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HCV Transmission Among  
Persons Who Inject Drugs (PWID) 
 Transmission risks 
 Injection duration 
 Injection frequency 
 Equipment sharing,  
    not just sharing needles  
 HCV prevalence  
 27 to 51% 
 
Burt, J Urban Health 2007.  Garfein R, J Urban Health 2013.  Keen L, Addict Behav  2014.  Amon JJ, Clin Infect Dis 2008  
Kwon J, AIDS 2009. 
 
 
 Incidence declined in  
    response to harm reduction for HIV  
    (e.g., syringe access programs) 
    HIV 
    HCV 
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Other Modes of HCV Transmission    
 Accidental needle stick in healthcare setting  
 HCV risk is 1.3%, HIV risk is 0.3% 
 18 healthcare-associated outbreaks from 2008 to 2013  
 223 cases involving over 90,550 at-risk persons notified 
 Non-injecting drug use (e.g., intranasal cocaine use)  
 Perinatal-infants born to HCV infected mothers  
 ~4% risk if mother infected with HCV  
 ~25% risk if mother co-infected with HCV and HIV 
 Sexual transmission is rare  
 HIV infected MSM at highest risk  
 Miscellaneous reported 
 Unregulated tattooing 
 
MSM: Men who have sex with men.  
 
Scheinmann, Drug and Alcohol Dependence  2006.  Weinbaum, MMWR 2003.  Gough, BMC Public Health 2010.  Mast, J Infect Dis, 2005.  
Marincovich B, Sex Transm Infect  2003.  Yaphe S, Sex Transm Inf  2012.  Bottieau, Eurosurveillance 2010.  Ackerman Z, J Viral Hepat  2000. 
Tohme RA, CID 2012. MMWR 2001. CDC/hepatitis.gov 
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Natural History of HCV Infection 
HIV: Human immunodeficiency virus.  HBV: Hepatitis B virus.   
Hepatocellular carcinoma  = Liver cancer.  Decompensated Cirrhosis = End stage liver disease. 
 
Ly KN, Clin Infect Dis. 2014.  Mahajan R, CID 2014 . 
Liver 
Transplant 
or  
Early 
Death 
In 20 years, 15-30% progress to cirrhosis  
Progression accelerated by HIV, HBV, alcohol use, and fatty liver   
20 years 
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Mortality from HCV is Increasing  
Ly KN, Clin Infect Dis 2014.  Mahajan R, CID 2014 . 
 From 1999 to 2010, HCV deaths increased by 50%   
 In 2010, 16,600 deaths 
 Mean age at death was 59 years 
 Two-fold increased mortality risk  
 Black non-Hispanic  
 American Indian/Alaskan Natives  
Mortality is under estimated 
 Only 33% of liver-related deaths among HCV infected 
persons are reported on Vital Records  
 At least 45-60% are not aware of their HCV 
infection 
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The Silent Growing Burden of Hepatitis C  
in the United States 
 Of 2.7 million HCV-infected people from NHANES   
 1.47 million will develop decompensated cirrhosis (DCC) 
 350,000 will develop hepatocellular carcinoma (HCC) 
 900,000 will die from HCV-related complications 
 
NHANES: Nutritional Health DCC: Liver failure.  HCC: Liver cancer.  
 
Rein D, Dig Liver Dis 2010. 
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The Birth Cohort: 
People Born during 1945 to 1965 
 
Historical high incidence 
 
 Six-fold higher prevalence than 
other US adults 3.39% vs 0.55% 
 
 Of all HCV infected US adults, 
81% were born in this cohort 
 
 Of all HCV-related deaths in US, 
73% were born in this cohort 
 
Smith, AASLD Liver Meeting 2011.  Armstrong, Ann Int Med 2006.  Kramer, Hepatology 2011.  Ly, Ann Int Med 2012. 
 
7.0 
6.0 
5.0 
4.0 
3.0 
2.0 
1.0 
0.0 
7.0 
6.0 
5.0 
4.0 
3.0 
2.0 
1.0 
0.0 
0 10 20 30 40 50 60 70 
1910 1920 1930 1940 1950 1960 1970 1980 1990 
Age at Time of Survey, y 
Year of Birth 
1988–1994 
1999–2002 
1988–1994 
1999–2002 
P
ro
p
o
rt
io
n
 A
n
ti
-H
C
V
-P
o
s
it
iv
e
, 
%
 
P
ro
p
o
rt
io
n
 A
n
ti
-H
C
V
-P
o
s
it
iv
e
, 
%
 1945 1965 
15 
One time Testing for HCV for  
Persons Born 1945-1965 
 
 Recommended by CDC in 2012 and USPSTF in 2013 
 
 Screening recommendation is solely based on year of 
birth, not on risk factors  
 Clinicians may be reluctant to ask about risks 
 Patients may be reluctant to disclose or may not recall risks 
  
 Persons found to be HCV infected need to link to care 
and treatment 
 
USPSTF: U.S. Preventive Services Task Force.   
MMWR Aug 2012.  Moyer VA, Ann Int Med 2013.  Shehab TM, J Viral Hepat  2001.   Shehab TM, Am J Gastroenterol 2003.   Serrante JM, 
Fam Med 2008.  Shehab TM, Hepatology 1999.  Roblin, Am J Man Care 2011.  Spradling, Hepatology 2012.  Zapata, Ann Hepatology 2010.  
Napper, AIDS Behav 2010.  Haley, Preven Med 2002. Torrone, AIDS  Pat Care 2010. Rein D, Ann Int Med 2012.  Eckman, CID, 2013.   
McEwan, Hepatology  2013.  McGarry, Hepatology 2012. Liu S, Plos One 2013.  
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Continued Risk-based Recommendations  
for HCV Screening 
 Risk-based screening 
 Major risk-past or present injection drug use 
 Other risks 
 Received blood/organs prior to June 1992 
 Received blood products made prior to 1987 
 Ever on chronic hemodialysis 
 Infants born to HCV-infected mothers  
 Intranasal drug use 
 Unregulated tattoo    
 History of incarceration  
 Medical  
 Persistently elevated ALT 
 HIV 
 
 
   
 
 
USPSTF: U. S. Preventive Services Task Force.  ALT: Alanine transaminase.  
 
MMWR Aug 2012.  Moyer VA, Ann Int Med 2013.   
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Benefits of Birth Cohort Testing 
 The Birth Cohort urgently needs to be identified to 
allow them the opportunity to be diagnosed and treated 
 
 Reduces risks of all-cause mortality by 50% 
 
 Reduces risks of hepatocellular carcinoma by 70% 
 
 
 
 
 
 
Rein D, Ann Int Med 2012.  Eckman, CID, 2013.   McEwan, Hepatology  2013.  McGarry, Hepatology 2012.  Liu S, Plos One 2013.  
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HCV Testing Cost Effectiveness 
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 Therapy 2012 
*CDC unpublished data.  TVR: Telapravir. 
http://www.prevent.org/National-Commission-on-Prevention-Priorities/Rankings-of-Preventive-Services-for-the-US-Population.aspx 
Rein D, Ann Int. Med 2012.     
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Improving the Continuum of Care  
for HCV Management 
0%
20%
40%
60%
80%
100%
120%
All HCV
infected
anti-HCV
tested
HCV care HCV RNA Treated SVR
SVR: Sustained viral response.  Holmberg S, NEJM  2013.     
 
 50%  
   38% 
      23% 
11%   
6% 
 ~ 3 million persons living with HCV in the United States  
 Current cure rates need to improve    
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Where Are We Now?  
 The burden of HCV-related disease is large 
 
 Reports of new HCV infections are increasing 
 
 CDC and USPSTF recommend HCV testing for persons  
 Born during 1945 to 1965  
 Who inject drugs, past or present 
 Others at risk 
 
 At least half of HCV-infected person are unaware of status  
  
 Access to HCV testing, care, and treatment must improve for 
patients to benefit from advances in therapy 
 
 
21 
Know More Hepatitis Campaign 
Times Square, May 2014 
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Hepatitis C: The Curative Era 
David Thomas, MD 
Stanhope Bayne Jones Professor of Medicine 
Chief of Infectious Diseases 
Johns Hopkins School of Medicine 
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Hepatitis C Treatment Responses 
Non-Response, Relapse, Sustained Viral Response 
AASLD HCV Treatment Guidelines, www.aasld.org   
Treatment Interval  
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SVR is Considered Cure  
Reinfection is Uncommon 
SVR: Sustained viral response 
Swain, Gastro 2010.  Manns, J Viral Hep 2014. 
N=636 
Percent with 5-year SVR 
5-year estimate of continued 
sustained viral response: 
99.2% (95% CI 98.1%-99.7%) 
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SVR is Considered Cure  
Reduction in Liver Failure 
Van der Meer, JAMA 2012.  Backus, Clin Gastro 2011.  Imazeki, Hepatology 2003.  Shiratori, Ann Intern Med 2005.  
Veldt, Ann Intern Med 2007.  Berenguer, Hepatology 2009.   
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SVR is Considered Cure 
Reduction in Hepatocelluar Carcinoma 
Van der Meer, JAMA 2012.  Backus, Clin Gastro 2011.  Imazeki, Hepatology 2003. Shiratori, Ann Intern Med 2005.  
Veldt, Ann Intern Med 2007.  Berenguer, Hepatology 2009.   
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Van der Meer, JAMA 2012.  Backus, Clin Gastro 2011.  Imazeki, Hepatology 2003.  Shiratori, Ann Intern Med 2005.  
Veldt, Ann Intern Med 2007.  Berenguer, Hepatology 2009.   
SVR is Considered Cure 
Reduction in All-Cause Mortality 
28 
Key Therapeutic Milestones in Reaching the 
Curative Era of HCV 
 FDA Approval of HCV Treatments 
1991 Interferon (IFN) 
1998 IFN and ribavirin 
2001 Pegylated IFN 
2011 Boceprevir and telaprevir 
2013 Sofosbuvir and simeprevir 
Thomas, Nat Med 2013. 
29 
High Rate of SVR 
Sofosbuvir, PegIFN, and Ribavirin for 12 weeks 
 
PegIFN; pegylated interferon. F0-3: Stages of liver fibrosis from none to moderate. F4: Severe liver fibrosis.  
Non-CC: Individuals with either CT or TT IL28-genotype.   
 
Lawitz, NEJM 2013.  
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High Rate of SVR for Genotype 1 HCV 
Ledipasvir (LDV) and Sofosbuvir (SOF) 
  
LDV/SOF naive F0-2, naive 
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SVR12: Sustained Viral Response for 12 weeks.  Non-VF: Non-virologic treatment failure. 8W: 8 weeks of therapy.   
12W: 12 weeks of therapy. 24W: 24 weeks of therapy. R: Ribavirin. 
  
Kowdley NEJM 2014. Afdhal, NEJM 2014.  
P
e
rc
e
n
t 
m
a
in
ta
in
in
g
 S
V
R
 1
2
 w
e
e
k
s
 
 a
ft
e
r 
e
n
d
 o
f 
th
e
ra
p
y
 
31 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
SOF/LDV 8W SOF/LDV/9669 6W SOF/LDV/9451 6W
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SVR12: Sustained Viral Response at 12weeks. SOF: Sofosbuvir.  LDV: Ledipasvir.  8W: 8 weeks. 6W: 6 weeks.  
 
Kohli, Poster 27LB, Conference on Retroviruses and Opportunistic Infections 2014.  NCT01431898. NCT01805882. 
SVR with 6 weeks of Sofosbuvir, Ledipasvir,  
and GS-9669 or GS-9451 
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Fewer Adverse Events with Newer Therapies  
Events Telaprevir, Peg, R 
n=292 
Boceprevir, Peg, R 
n=205  
Serious adverse event (SAE) 132 (45%) 67 (33%) 
Premature discontinuation 66 (23%) 54 (26%) 
Discontinuation due to SAE 43 (15%) 15   (7%) 
Hepatic decompensation  6  (2%)  6   (3%) 
Serious rash 14  (5%)  0 
Events LDV-SOF x 8 wk 
n=215 
LDV-SOF RBV x 8 wk 
n=216 
Serious adverse event (SAE) 4  (2%) 1 (<1%) 
Discontinuation due to SAE 0 1 (<1%) 
Peg=Pegylated interferon. R=Ribavirin. LDV=Ledipasvir. SOF=Sofosbuvir.  
 
Hezode J Hepatol 2013.  Knowdley, NEJM 2014. 
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Rapid Progress in Interferon-sparing  
HCV Treatment 
 Genotype 1 
 *Simeprevir and sofosbuvir (not FDA approved, filed) 
 *Sofosbuvir and ribavirin (alternative) 
 Sofosbuvir and ledipasvir (filed) 
 ABT 450/r, ombitasvir, dasabuvir, +/- ribavirin (filed)  
 Daclatasvir and asunaprevir (filed) 
 MK5172, MK8742, +/- ribavirin (phase 3) 
 
 Genotype 2 and 3 
 *Sofosbuvir and ribavirin 
 
*the individual components of these regimens are already available  in June 2014. 
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Expert Guidelines for HCV Screening, 
Management and Treatment 
Copyright © 2014 by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. 
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Evaluating the Cost Effectiveness  
of New Therapies 
Rein Ann Intern Med 2012 and unpublished data.  Younoussi, J Hepatol 2014.  Hagan, Hepatology 2014.  Linas, AIDS 2014.  
Deuffic-Burban,  J Hepatol 2014.  Brogan, Plos One 2014 . 
 In 2011, average wholesale acquisition costs of 
drugs alone were $32,000 to over $100,000  
 Quality adjusted life years for those regimens 
considered reasonable   
 New regimens are $100,000 to $175,000 in US 
 Incremental cost benefits have been demonstrated 
 Evaluating cost effectiveness of new regimens also 
has to reflect the increased efficacy of the treatment 
(cost/cure)  
36 
Steady Progress in Treatment Efficacy Has Increased 
the Proportion of Persons Who Are Cured  
Thomas, Nat Med 2013. 
IFN 
IFN and ribavirin 
PegIFN and ribavirin 
PegIFN, RBV, and protease inhibitor 
All oral 
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Greater Uptake Will Maximize Potential  
Global Impact 
Thomas, Nat Med 2013. 
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Conclusions: HCV Curative Era 
 HCV can be cured 
 
 Curing HCV reduces mortality and morbidity 
 
 Curing HCV reduces the risk of HCV transmission 
 
Major challenges to global control are screening and 
testing and lack of treatment access 
39 
Steps Toward Ending Hepatitis C in the US 
Phillip Coffin, MD, MIA 
Director of Substance Use Research 
San Francisco Department of Public Health 
University of California San Francisco 
40 
Essential Goals to Eliminate HCV 
 Prevent sequelae of advancing liver disease in 
those already infected 
 Baby Boomers, born 1945-1965 
 Many don’t know they are infected 
 
 Prevent new or “incident” infections 
 Persons who inject drugs (PWID) 
 Unsafe healthcare practices 
 Sexual exposures in immunocompromised individuals 
 
41 
Continuum of Care Model for HIV  
Screening 
and Testing 
Diagnosis Management Treatment Virologic 
Suppression 
Linkage Engagement / 
Retention 
Engagement / 
Retention 
Long-term 
Reduction 
in 
Prevalence 
and 
Incidence 
of HIV   
Primary 
Prevention 
Adapted from: Das M, Conference on Retroviruses and Opportunistic Infections 2014. 
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Continuum of Care Model for HCV  
Screening 
and Testing 
Diagnosis Management Treatment Cure 
Linkage Engagement / 
Retention 
Engagement / 
Retention 
Long-term 
Decrease 
in 
Prevalence 
and 
Incidence 
of HCV   
HCV screening test 
 
 
Primary Prevention – Syringe Exchange, 
Condoms, Substance Use Treatment  
 Screening tests would be opt-out  
 EHR designed to have automated reminders 
 Healthcare-level tracking to ensure baby boomers get screened 
 
 
Adapted from: Das M, Conference on Retroviruses and Opportunistic Infections 2014. 
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Continuum of Care Model for HCV  
Screening 
and Testing 
Diagnosis Management Treatment Cure 
Linkage 
Engagement / 
Retention 
Engagement / 
Retention 
Long-term 
Decrease in 
Prevalence 
and 
Incidence 
of HCV   
 Simplify two-step process of screening then RNA confirmatory through reflexive testing 
 Healthcare level systems could match positive screens to ensure follow-up testing 
 Public health systems cannot track follow-up testing, negative test results not reportable 
 Evaluate effectiveness of screening efforts by comparing to stage of fibrosis at diagnosis  
RNA confirmatory testing            
Staging of fibrosis 
Adapted from: Das M, Conference on Retroviruses and Opportunistic Infections 2014. 
44 
Continuum of Care Model for HCV  
Screening 
and Testing 
Diagnosis Management Treatment Cure 
Linkage 
Engagement / 
Retention 
Engagement / 
Retention 
Long-term 
Decrease in 
Prevalence 
and 
Incidence 
of HCV   
 Patient management should include referral to substance use disorder treatment and 
brief alcohol interventions  
 Healthcare-level systems could track serial ALT to ensure periodic evaluation is done  
 
 
Screening for syndemics, Vaccination, Risk-reduction counseling, 
Evaluation for treatment including liver function, Genotyping  
ALT: Alanine transaminase.  Syndemic infections include Hepatitis A, Hepatitis B and HIV.  
 
  Adapted from: Das M, Conference on Retroviruses and Opportunistic Infections 2014. 
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Continuum of Care Model for HCV  
Screening 
and Testing 
Diagnosis Management Treatment Cure 
Linkage 
Engagement / 
Retention 
Engagement / 
Retention 
Long-term 
Decrease in 
Prevalence 
and 
Incidence 
of HCV   
 Historically, treatment uptake was major barrier  
 New regimens should improve treatment uptake 
 New barriers such as cost and access may limit potential impact of new regimens 
 Interventions could address these new barriers 
 If negative RNA results were reportable, public health systems could track SVR 
Serial RNA measurements 
SVR: Sustained viral response.  
Adapted from: Das M, Conference on Retroviruses and Opportunistic Infections 2014. 
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Screening 
and Testing 
Diagnosis Management Treatment Cure 
SVR vs. re-infection 
monitoring through 
RNA measurements 
Continuum of Care Model for HCV  
Linkage 
Engagement / 
Retention 
Engagement / 
Retention 
Long-term 
Decrease in 
Prevalence 
and 
Incidence 
of HCV   
 Sustained viral response (SVR) is monitored 
through repeated negative RNA results over time 
 Healthcare systems could track this data 
 Public health systems cannot track unless negative 
RNA results become reportable 
Adapted from: Das M, Conference on Retroviruses and Opportunistic Infections 2014. 
47 
Potential Reduction in HCV-Related Liver Deaths  
from Expanded Screening and Treatment Regimens 
Coffin, CID 2012 (modified for new treatment regimens, direct-acting agents). 
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Potential Reduction in HCV-Related Liver Deaths 
by Treatment Strategy based on Liver Fibrosis 
F2-F4: Stages of liver fibrosis including moderate (F2), severe (F3), and cirrhosis (F4) 
Coffin, CID 2012 (modified for novel direct-acting agents). 
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49 
Expanding Treatment in Primary Care 
to Meet Demand 
AASLD: American Association for the Study of Liver Diseases.  IDSA: Infectious Diseases Society of America.  IFN: Interferon.   
ECHO: Extension for Community Healthcare Outcomes. 
Rustgi, Hepatology 2008. Arora, NEJM 2011. Centers for Medicare and Medicaid.  
 HCV specialists 
 2,335 US-based AASLD 
members in 2010 
 Only 5,200 unique prescribers of 
HCV therapeutics for  
    January-March 2014 
 Primary care & other providers 
 209,000 practicing PCPs in 2010 
 Similar SVR with ECHO support 
for IFN-based Rx 
 9,000 IDSA members in 2013 
 New therapies are 8-12 weeks, all-oral, with minimal side effects 
50 
Strategies to Prevent New Infections of HCV 
 Major risk factor for new infections is IV drug use 
 Largest numbers of new infections are in PWIDs 
 
 Strategies to reduce HCV in PWIDs   
 Syringe access programs and education programs 
 
 Treatment as Prevention (TasP) 
 
 Medication-assisted treatment for substance use disorder 
 Low threshold methadone treatment programs 
 
 Vaccine research 
 Early Phase 2 stages 
 
PWIDs: Persons who inject drugs 
51 
Syringe Access Programs Impact On HCV 
Prevalence and Incidence 
NSP: Needle & syringe program.  
Kwon J, AIDS 2012.  
Impact on Prevalence Impact on Incidence 
    
52 
Treatment as Prevention (TasP) for HCV 
 Interrupt Secondary Transmission 
 
 Maximize Impact on Incidence  
 Target active injectors 
 Social network-based recruitment strategy 
 PWID in high prevalence areas 
 Optimize treatment delivery 
 Patient navigation programs 
 Conditional cash transfer programs 
 Directly observed therapy 
 
 
 
53 
Potential Impact of Treatment as Prevention 
based on Prevalence  
 Prevalence in many 
US cities falls close 
to 50%-65% 
 
 Treating just 8% of 
active injectors per 
year would reduce 
prevalence by 50% to 
90% in 15 years  
MartinHepatology 2013. 
 
54 
Value of Comprehensive Prevention: 
TasP, Syringe Access and Opioid Substitution  
TasP: Treatment as prevention. OST: Opioid substitution treatment.  HCNSP: Syringe access programming.   
 
Martin, Clinical Infectious Diseases 2013. 
 
55 
Concerns and Research Needs for HCV TasP 
 Acceptability of new treatments to PWIDs 
 
 Impact of acute infection on treatment and transmission 
 
 Drug resistance archiving 
 
 Efficacy of behavioral interventions to reduce reinfection 
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To Reduce and Perhaps Eliminate HCV 
 Increase priority – widen public recognition of urgency of action 
 
 Increase screening – follow USPSTF recommended screening 
 
 Improve testing algorithm – simplify HCV screening and diagnosis 
  
 Enhance surveillance – change policies to improve utility of data 
 
 Expand clinical workforce – allow for primary care management 
 
 Increase treatment availability – modify treatment regimens 
  
 Reduce payer restrictions – increase number of therapeutics   
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CDC PUBLIC HEALTH GRAND ROUNDS  
The 25th Anniversary of the  
Discovery of the Hepatitis C Virus  
Looking Back to Look Forward 
